A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study

In vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors

“…2 A combination of granulocyte colony-stimulating factor (G-CSF) and the CXCR4 antagonists AMD3100 (Mozobil, Plerixa) has been shown to efficiently mobilize primitive progenitor cells in animal models and in humans. 3 A problem for in vivo HSPC transduction is the low number of HSPCs in the BM. Only about 1 in 10 8 nucleated marrow cells are HSPCs 4 ; the vast majority of cells in the BM are blood cell progenitor cells with different levels of lineage commitment.…”

Large volume leukapheresis: Efficacy and safety of processing patient’s total blood volume six times

“…If role of LVL is considered in setting of new mobilizing agents, such as plerixafor used in case of previously unsuccessful mobilization [52,53], there is no doubt that LVL should be performed to collect maximum PBSCs in one procedure. From the data presented, we conclude that processing of 6 TBVs during LVL is efficient and safe technique, which significantly reduces the number of aphereses needed to obtain target number of CD34+ cells.…”

The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation

“…45,46 It has been suggested that the more primitive HSCs mobilized by plerixafor in combination with G-CSF may have a greater capacity for reconstituting bone marrow compared with those mobilized by G-CSF alone. 47 In conclusion, the availability of plerixafor is a significant advance, increasing the number of patients for whom auto-HSC transplantation is a potentially effective treatment option and increasing the number of patients able to proceed, in as short a time as possible, to high-dose chemotherapy. On the basis of currently available mobilization regimens, we expect plerixafor to become increasingly the mobilization method of choice for MM, NHL and Hodgkin's lymphoma patients likely to benefit from high-dose chemotherapy.…”

“…Plerixafor alone may also have a role in circumstances in which G-CSF or Figure 1 HSC mobilization and apheresis schedule for plerixafor in conjunction with G-CSF as described in phase III trials. 46,47 Editorial chemotherapy-based mobilization is not suitable, although HSC mobilization is modest compared with plerixafor and G-CSF in combination G-CSF. 24 The current indication in Europe for plerixafor is 'in combination with G-CSF to enhance mobilization of HSCs to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and MM, whose cells mobilize poorly'.…”